Xinyin Liu - Concepedia

Author

Xinyin Liu

Nanjing Medical University ORCID

Also Known As

, Xinyin Liu

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Nanjing Medical University Jiangsu Province Hospital

About

Xinyin Liu is an author at Nanjing Medical University specializing in medicine, tumor biology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	106
2	Cell Biology	3	3	106
3	Health Sciences	1	1	26
4	Natural Sciences	1	1	16
5	Biochemistry	1	1	16

Xinyin Liu

Publications

379

Citations

H-Index

Page 1

	Year	Citations
LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC Xinyin Liu, Xiyi Lu, Fuxi Zhen, Molecular Therapy — Nucleic Acids	2019	135
A Novel Long Non-Coding RNA, SOX21-AS1, Indicates a Poor Prognosis and Promotes Lung Adenocarcinoma Proliferation Xiyi Lu, Chenjun Huang, Xuezhi He, Cellular Physiology and Biochemistry	2017	65
Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer Xiyi Lu, Jing Wang, Wei Wang, Oncogene MedicineCancer GenomicsCopy Number AmplificationPhase SeparationCancer Genetics	2022	64
EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer Xiyi Lu, Xuezhi He, Jun Su, Molecular Therapy — Nucleic Acids	2018	38
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop Chen Zhang, Wenxin Zhou, Hai Xu, Oncogene Egfr-tki ResistanceCancer-associated FibroblastsCancer BiologyTumor BiologyPositive Feedback Loop	2025	26
Association of <i>KDR</i> mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors. Yanan Cui, Pengpeng Zhang, Xiaowen Liang, PubMed	2022	25
Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer Chen Zhang, Xiyi Lu, Xinyin Liu, Oxidative Medicine and Cellular Longevity PathologyMolecular BiologyRedox BiologyTumor BiologyOxidative Stress	2023	16
Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Yanan Cui, Xinyin Liu, Yuemin Wu, Frontiers in Oncology	2022	10

Page 1